CCP Trials

Facilitating collaboration in translational clinical cancer research

©Kurhan/fotolia.com

©Kurhan/fotolia.com

The CCP Trial is one of four essential Task Forces to facilitate collaboration in translational clinical cancer research.

The task force is a clinical trial network of the consortium with the task to exchange information on the currently available trial services. This network is instrumental to implement the use of the newly established CCP databases for the purpose of trial feasibility analyses (site-specific as well as across sites) and serves as a think-tank for the further development of CCP tools and services. From each side the heads of the local trial units and additional co-workers are members of the DKTK working group CCP trials (see below).

Within the DKTK, a high number of investigator-initiated clinical trials from phase I to phase IV is being conducted. DKTK centers coordinate large trial groups in GI Cancer (Gastric, Rectal, Colon, Pancreatic), hematologic malignancies (Myeloma, ALL, AML, childhood leukemias, lymphomas), Lung Cancer, Glioma, renal cell carcinoma and others (see overview on studygroups here).

Each of the DKTK centers is strongly involved in multiple additional multicenter trials. Investigator-initiated early clinical trials are being performed at each DKTK site, mostly in dedicated early clinical trial units.

By now a central overview on the trial activities, a trial registry was built that allows each site to announce their open clinical trials that are open for accrual at any of the participating sites. This registry contains a concentrated dataset as clinical-trial-meta-data, including a search function by molecular targets, investigators, sites and cancer entities.

Joint activities of the trial network also include workshops on legal, regulatory and procedural aspects of clinical trials to harmonize and standardize the work of the trial centers at the sites. They are jointly organized by the CCP, the Paul-Ehrlich-Institute, the major regulatory authority for the clinical development of biologicals in Germany and the School of Oncology, regarding “Education of Young Scientists”). Further information on special regulatory trainings in Good-Clinical-Practice are collected in a education database for a focused search by target group, content, duration, costs, locality and displaying relevant contact data.

Coordinating contact

For more information please contact

Kristina Ihrig, Frankfurt